array(3) { ["company_details"]=> array(13) { ["name"]=> string(18) "SEQIRUS UK LIMITED" ["slug"]=> string(27) "f592d-gb-seqirus-uk-limited" ["logo"]=> NULL ["description"]=> NULL ["address_street"]=> string(5) "Point" ["address_place"]=> string(10) "MAIDENHEAD" ["address_region"]=> NULL ["founding_date"]=> string(10) "2015-05-29" ["website_domain"]=> string(13) "seqirus.co.uk" ["website_url"]=> string(25) "https://www.seqirus.co.uk" ["industry_codes"]=> array(2) { [0]=> string(54) "Offices of Holding Companies, Not Elsewhere Classified" [1]=> string(43) "Business Services, Not Elsewhere Classified" } ["employee_count"]=> int(227) ["article_count"]=> int(15) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(75) "BRIEF—Expanded UK indication for CSL Seqirus’ flu jab in young children" ["snippet_en"]=> string(100) "CSL Seqirus has received approval from the Medicines and Healthcare products Regulatory Agency( MHRA" ["url"]=> string(111) "https://www.thepharmaletter.com/in-brief/brief-expanded-uk-indication-for-csl-seqirus-flu-jab-in-young-children" ["image_url"]=> NULL ["source"]=> string(19) "thepharmaletter.com" ["publication_date"]=> string(10) "2023-11-13" ["categories"]=> array(1) { [0]=> string(11) "Regulations" } } [1]=> array(7) { ["title_en"]=> string(72) "Include community pharmacy in early vaccination planning, sector demands" ["snippet_en"]=> string(136) "Pharmacy bodies have called for winter 2024/25 vaccination planning to include community pharmacy ‘at an appropriately early stage’." ["url"]=> string(140) "https://www.thepharmacist.co.uk/clinical/immunology-and-vaccination/include-community-pharmacy-in-early-vaccination-planning-sector-demands/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/4200966e-5d20-4089-9c71-b2a014bbea90" ["source"]=> string(19) "thepharmacist.co.uk" ["publication_date"]=> string(10) "2023-10-26" ["categories"]=> array(2) { [0]=> string(16) "Customer Welfare" [1]=> string(24) "Access and affordability" } } [2]=> array(7) { ["title_en"]=> string(65) "Deal struck to produce vaccines in UK for any future flu pandemic" ["snippet_en"]=> string(74) "The jabs would be made at CSL Seqirus’s manufacturing plant in Liverpool" ["url"]=> string(73) "https://www.aol.co.uk/news/deal-struck-produce-vaccines-uk-084727696.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/47467a4a-69be-46da-8c5b-51f60442b052" ["source"]=> string(9) "aol.co.uk" ["publication_date"]=> string(10) "2023-09-26" ["categories"]=> array(1) { [0]=> string(8) "Epidemic" } } [3]=> array(7) { ["title_en"]=> string(103) "UK puts CSL Seqirus on standby for flu pandemic preparedness, with vaccines to be produced in Liverpool" ["snippet_en"]=> string(290) "The last flu pandemic came and went in 2009—with lots of advanced hype and much less effect. When the next flu pandemic arrives and its severity is anyone’s guess. Either way, the U.K.| The U.K. has inked a four-year deal for CSL Seqirus to develop and manufacture more than 100 million" ["url"]=> string(124) "https://www.fiercepharma.com/manufacturing/uk-enlists-csl-seqirus-standby-flu-pandemic-preparedness-shots-produced-liverpool" ["image_url"]=> string(78) "https://images.businessradar.com/articles/abf58dc0-d5eb-4cfb-8ca9-94c6e81e1a00" ["source"]=> string(16) "fiercepharma.com" ["publication_date"]=> string(10) "2023-09-26" ["categories"]=> array(3) { [0]=> string(18) "Ecological Impacts" [1]=> string(8) "Epidemic" [2]=> string(14) "Product Launch" } } [4]=> array(7) { ["title_en"]=> string(43) "UKHSA reaches vaccine deal with CSL Seqirus" ["snippet_en"]=> string(78) "Agreement will provide timely boost to pandemic preparedness against influenza" ["url"]=> string(84) "https://www.pharmatimes.com/news/ukhsa_reaches_vaccine_deal_with_csl_seqirus_1501000" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c51b4045-17a0-4e12-b772-269046637f12" ["source"]=> string(15) "pharmatimes.com" ["publication_date"]=> string(10) "2023-09-26" ["categories"]=> array(3) { [0]=> string(15) "Deals & Tenders" [1]=> string(21) "Competitive Behaviour" [2]=> string(8) "Epidemic" } } [5]=> array(7) { ["title_en"]=> string(65) "Deal struck to produce vaccines in UK for any future flu pandemic" ["snippet_en"]=> string(73) "The jabs would be made at CSL Seqirus's manufacturing plant in Liverpool." ["url"]=> string(127) "http://www.irishnews.com/news/uknews/2023/09/26/news/deal_struck_to_produce_vaccines_in_uk_for_any_future_flu_pandemic-3644737/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/32eca171-8fdf-4e54-b6e3-b078f33c54b1" ["source"]=> string(13) "irishnews.com" ["publication_date"]=> string(10) "2023-09-26" ["categories"]=> array(1) { [0]=> string(8) "Epidemic" } } [6]=> array(7) { ["title_en"]=> string(88) "CSL Seqirus highlights impact of flu vaccines on reducing strain on healthcare resources" ["snippet_en"]=> string(94) "Flu vaccines for older adults in France could potentially reduce hospitalisations by up to 30%" ["url"]=> string(131) "https://www.pmlive.com/pharma_news/csl_seqirus_highlights_impact_of_flu_vaccines_on_reducing_strain_on_healthcare_resources_1500602" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1acbf60f-539e-43c3-ad70-41e8a083fe8f" ["source"]=> string(10) "pmlive.com" ["publication_date"]=> string(10) "2023-09-19" ["categories"]=> array(0) { } } [7]=> array(7) { ["title_en"]=> string(122) "CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources" ["snippet_en"]=> string(159) "/PRNewswire/ -- CSL Seqirus, a business of CSL (ASX:CSL), today unveiled new analyses that underscore the potential of influenza vaccines in alleviating the..." ["url"]=> string(180) "https://www.prnewswire.co.uk/news-releases/csl-seqirus-shares-data-demonstrating-the-potential-for-influenza-vaccination-to-reduce-the-burden-on-healthcare-resources-301929860.html" ["image_url"]=> NULL ["source"]=> string(16) "prnewswire.co.uk" ["publication_date"]=> string(10) "2023-09-18" ["categories"]=> array(3) { [0]=> string(16) "Customer Privacy" [1]=> string(13) "Data Security" [2]=> string(12) "Stock Market" } } [8]=> array(7) { ["title_en"]=> string(100) "Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization A" ["snippet_en"]=> string(301) "EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was metAn additional Phase 3 booster study demonstrating non-inferiority of immune response compared to Comirnaty® and superiority of ARCT-154 in neutralizing antibody response against SARS-CoV-..." ["url"]=> string(151) "https://www.pharmiweb.com/press-release/2023-09-05/arcturus-therapeutics-and-csl-announce-european-medicines-agency-validates-marketing-authorization-a" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3fa2355d-cfbe-47da-aecf-d2207dff45f4" ["source"]=> string(13) "pharmiweb.com" ["publication_date"]=> string(10) "2023-09-05" ["categories"]=> array(1) { [0]=> string(18) "Ecological Impacts" } } } ["category_annotations"]=> array(9) { [0]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(5) } [1]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(2) } [2]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(2) } [3]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(1) } [4]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(1) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(1) } [6]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(1) } [7]=> array(2) { ["name"]=> string(18) "Ecological Impacts" ["count"]=> int(1) } [8]=> array(2) { ["name"]=> string(19) "Government Policies" ["count"]=> int(1) } } } f592d-gb-seqirus-uk-limited